Chán ăn

Walsh D, Donnelly S, Rybicki L. The symptoms of advanced cancer: relationship to age, gender, and performance status in 1000 patients. Support Care Cancer 2000; 8: 175–9 Tamburini M, Brunelli C, Rosso S, et al. Prognostic value of quality of life scores in terminal cancer patients. J Pain Symptom Manage 1996; 11: 32–41 Loprinzi CL, Laurie JA, Wieand HS, et al. Prospective evaluation of prognostic variables from patient-completed questionnaires: North Central Cancer Treatment Group. J Clin Oncol 1994; 12: 601–7 Vigano A, Dorgan M, Buckingham J, et al. Survival prediction in terminal cancer patients: a systemic review of the medical literature. Palliat Med 2000; 14: 363–74 Theologides A, Ehlert J, Kennedy BJ. The calorie intake of patients with advanced cancer. Minn Med 1976; 59: 526–9 Staal-vandenBrekel AJ, Schols AMW, ten Velde GP, et al. Analysis of energy balance in lung cancer patients. Cancer Res 1994; 54: 6430–3 Staal-van den Brekel AJ, Dentener MA, Schols AM, et al. Increased resting energy expenditure and weight loss are related to a systemic inflammatory response in lung cancer patients. J Clin Oncol 1995; 13: 2600–5 Levine JA, Emery PW. The significance of learned food aversions in the aetiology of anorexia associated with cancer. Br J Cancer 1987; 56: 73–8 Bartoshuk LM. Chemosensory alterations and cancer therapies. NCI Monogr 1990; 9: 179–84 MacCarthy-Leventhal EM. Post-radiation mouth blindness. Lancet 1959; II: 1138–9 Holmes S. Food avoidance in patients undergoing cancer chemotherapy. Support Care Cancer 1993; 6: 326–30 Ripamonti C, Zecca E, Brunelli C, et al. A randomized, controlled trial to evaluate the effects of zinc sulfate on cancer patients with taste alterations caused by head and neck irradiation. Cancer 1998; 82: 1938–45 Hopwood P, Stephens RJ. Depression in patients with lung cancer: prevalence and risk factors derived from quality of life data. J Clin Oncol 2000; 18: 893–903 Jatoi A, Loprinzi CL. An update: cancer-associated anorexia as a treatment target. Current Opin Clin Nutr Metab Care 2001; 4: 179–82 Jatoi A, Loprinzi CL, Sloan JA, et al. Neuropeptide Y, leptin, and cholecystokinin 8 in patients with advanced cancer and anorexia: a North Central Cancer Treatment Group exploratory investigation. Cancer 2001; 92: 629–33 Jatoi A, Loprinzi CL. Current management of cancer-associated anorexia and weight-loss. Oncology (Huntingt) 2001; 15: 497–502, discussion 508-10 Perioperative total parenteral nutrition in surgical patients: the Veterans Affairs Total Parenteral Nutrition Cooperative Study Group. N Engl J Med 1991; 325 (8): 525–32 Fan ST, Lo M, Lai ECS, et al. Perioperative nutritional support in patients undergoing hepatectomy for hepatocellular carcinoma. N Engl J Med 1994; 331: 1547–52 Weisdorf S A, Lysne J, Wind D, et al. Positive effect of prophylactic total parenteral nutrition on long-term outcome of bone marrow transplantation. Transplantation 1987; 43: 833–8 Geels P, Eisenhauer E, Bezjak A, et al. Palliative effect of chemotherapy: objective tumor response is associated with symptom improvement in patients with metastatic breast cancer. J Clin Oncol 2000; 18: 2395–405 Loprinzi CL, Ellison NM, Schaid DJ, et al. Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. J Natl Cancer Inst 1990; 82: 1127–32 Jatoi A, Windschitl HE, Loprinzi CL, et al. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. J Clin Oncol 2002; 20: 567–73 Nelson K, Walsh D, Deeter P, et al. A phase II study of delta-9-tetrahydrocannabinol for appetite stimulation in cancer-associated anorexia. J Palliat Care 1994; 10: 14–8 Jatoi A, Kumar S, Sloan J, et al. On appetite and its loss. J Clin Oncol 2000; 18: 2930–2 Moertel CG, Schutt AJ, Reitemeier RJ, et al. Corticosteroid therapy of preterminal gastrointestinal cancer. Cancer 1974; 33: 1607–9 Loprinzi CL, Kugler JW, Sloan JA, et al. Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. J Clin Oncol 1999; 17: 3299–306 Naing KK, Dewar JA, Leese GP. Megestrol acetate therapy and secondary adrenal suppression. Cancer 1999; 86: 1044–9 Nishimura R, Nagao K, Miyayama H, et al. An analysis of serum interleukin-6 levels to predict benefits of medroxyprogesterone acetate in advanced or recurrent breast cancer. Oncology 2000; 59: 166–73 Jatoi A, Yamashita J, Sloan JA, et al. Does megestrol acetate down-regulate interleukin-6 in patients with cancer-associated anorexia and weight loss?: a North Central Cancer Treatment Group investigation. Support Care Cancer 2002; 10: 71–5 Lissoni P, Paolorossi F, Tancini G, et al. Is there arole for melatonin in the treatment of neoplastic cachexia? Eur J Cancer 1996; 32A: 1340–3 Boasberg PD, O’Day SJ, Weisberg M, et al. Thalidomide induced cessation of weight loss and improved sleep in advanced cancer patients with cachexia [abstract]. Proc Am Soc Clin Oncol 2000; 19: 2396A Eisen T, Boshoff C, Mak I, et al. Continuous low dose thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br J Cancer 2000; 82: 812–7 Bruera E, Belzile M, Neumann C, et al. A double blind, crossover study of controlled-release metoclopramide and placebo for the chronic nausea and dyspepsia for advanced cancer. J Pain Symptom Manage 2000; 19: 427–35 Torelli GF, Meguid MM, Moldawer LL, et al. Use of recombinant human soluble TNF receptor in anorectic tumor-bearing rats. Am J Physiol 1999; 277: R850–5 Kawamura I, Morishita R, Tomita N, et al. Intramural injection of oligonucleotides to the NF kappa B binding site inhibits cachexia in a mouse tumor model. Gene Ther 1999; 6: 91–7 Agteresch HJ, Dagnelie PC, vanderGaast A, et al. Randomized clinical trial of adenosine 5′-triphosphate in patients with advanced non-small cell lung cancer. J Natl Cancer Inst 2000; 92: 321–8 Edelman MJ, Gandara DR, Meyers FJ, et al. Serotonergic blockade in the treatment of the cancer anorexia-cachexia syndrome. Cancer 1999; 86: 684–8 Wigmore SJ, Barber MD, Ross JA, et al. Effect of oral eicosapentaenoic acid on weight loss in patients with pancreatic cancer. Nutr Cancer 2000; 36: 177–84 Gogos CA, Ginopoulos P, Salsa B, et al. Dietary omega-3 polyunsaturated fatty acids plus vitamin E restore immunodeficiency and prolong survival for severely ill patients with generalized malignancy: a randomized controlled trial. Cancer 1998; 82: 395–402 Goldberg RM, Loprinzi CL, Mailliard JA, et al. Pentoxyfylline for treatment of cancer anorexia and cachexia? A randomized, double-blind, placebo-controlled trial. J Clin Oncol 1995; 13: 2856–9 Fong Y, Moldawer LL, Marano M, et al. Cachectin/TNF or IL-1 alpha induces cachexia and redistribution of body proteins. Am J Physiol 1989; 256: R659–65 Gelin J, Moldawer LL, Lonnroth C, et al. Role of endogenous tumor necrosis factor alpha and interleukin 1 for experimental tumor growth and the development of cancer cachexia. Cancer Res 1991; 51: 415–21 Loprinzi CL, Goldberg RM, Su JQ, et al. Placebo-controlled trial of hydrazine sulfate in patients with newly diagnosed non-small cell lung cancer. J Clin Oncol 1994; 12: 1126–9